Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested Jiangsu Dingtai Pharmaceutical Research (Dingtai Yao Yan) to provide supplementary explanations regarding equity changes and other matters as part of its application for listing on the Hong Kong Stock Exchange [1][2][3] Group 1: Equity Changes - The CSRC requires Dingtai Yao Yan to clarify the pricing basis for past capital increases and equity transfers, including whether actual contributions were made and if there are any unfulfilled obligations or defects in the contribution methods [1] - The company must provide updates on the overseas investment procedures related to the establishment of Hong Kong Dingtai and the ODI procedures concerning the investment in Xellar Ltd [1] - A review of historical shareholding arrangements and the involvement of external advisors in employee stock ownership plans is mandated to ensure compliance and identify any potential conflicts of interest [1][2] Group 2: Shareholder Situation - Dingtai Yao Yan is required to justify the reasonableness of the share prices for new shareholders over the past 12 months and to clarify any discrepancies in these prices [2] - The company must confirm whether shares held by four shareholders obtained through the share transfer system are subject to pledges, freezes, or other rights defects [2] Group 3: Business Operations - The company needs to detail its business scope, which includes medical research, gene diagnosis and treatment technology development, and breeding of protected wildlife, ensuring that it has the necessary qualifications and complies with foreign investment policies [2] - A legal opinion is required to confirm whether the company or its subsidiaries fall under any prohibitive circumstances for overseas issuance and listing as per regulatory guidelines [2][3] Group 4: Listing and Full Circulation - Dingtai Yao Yan must explain any inconsistencies between the proposed listing plan and the materials submitted, including the prospectus [3] - The company is also required to disclose the status of shares held by shareholders participating in the "full circulation" and whether these shares are subject to any rights defects [3] - Details regarding the company's previous listing on the National Equities Exchange and Quotations (NEEQ) and the reasons for its termination, as well as plans for A-share listing, must be provided [3]

Core Points - The China Securities Regulatory Commission (CSRC) has issued a notice confirming the overseas listing and "full circulation" of Shanghai Linqingxuan Cosmetics Group Co., Ltd [1] - Linqingxuan plans to issue up to 16.061 million overseas listed ordinary shares and list them on the Hong Kong Stock Exchange [1] - A total of 14 shareholders intend to convert 92.127 million shares of unlisted domestic shares into overseas listed shares for trading on the Hong Kong Stock Exchange [1] Summary by Sections Company Overview - Shanghai Linqingxuan Cosmetics Group Co., Ltd is preparing for an overseas listing and has received confirmation from the CSRC [1] - The company aims to enhance its market presence by listing on the Hong Kong Stock Exchange [1] Shareholder Actions - 14 shareholders will convert a total of 92.127 million shares into overseas listed shares [2] - The largest shareholder, Sun Laichun, will convert approximately 28.816 million shares [2] Regulatory Compliance - The CSRC requires Linqingxuan to report any significant events through the CSRC's management information system until the completion of the overseas listing [1] - After the overseas issuance and listing, Linqingxuan must report the listing status within 15 working days and comply with relevant laws and regulations [1] - If the company does not complete the overseas issuance and share conversion within 12 months, it must update its filing materials [1]

Core Points - The China Securities Regulatory Commission (CSRC) has issued a filing notice confirming the overseas listing and full circulation of unlisted shares for Suzhou Youlesai Shared Services Co., Ltd [1][2] - Suzhou Youlesai plans to issue up to 26,833,500 overseas listed ordinary shares and convert a total of 67,317,705 unlisted shares held by 18 shareholders into overseas listed shares [1][3] - The filing notice stipulates that if Suzhou Youlesai does not complete the overseas listing and share conversion within 12 months, it must update its filing materials [2] Company Details - The 18 shareholders participating in the full circulation and their respective share conversion amounts are detailed, with the largest shareholder, Sun Yan'an, holding 36,093,750 shares [3] - The total number of shares to be converted by the shareholders amounts to 67,317,705 [3]

Core Points - The China Securities Regulatory Commission (CSRC) has issued a notice regarding the overseas listing and "full circulation" of shares for Dipu Technology Co., Ltd [1][2] - The company plans to issue up to 115,000,000 ordinary shares for overseas listing on the Hong Kong Stock Exchange [2] - A total of 36 shareholders intend to convert 300,000,000 unlisted domestic shares into overseas listed shares [2] Summary by Sections Company Actions - Dipu Technology Co., Ltd is set to issue a maximum of 115 million shares for overseas listing [2] - The company has 36 shareholders who will convert a total of 300 million unlisted domestic shares into shares for overseas listing [2][4] Regulatory Requirements - The company must report any significant events to the CSRC from the date of the notice until the completion of the overseas listing [2] - After the overseas listing, the company is required to report the listing status to the CSRC within 15 working days [2] - The company must comply with all relevant laws and regulations during the overseas issuance and share conversion process [2] Shareholder Details - A detailed list of shareholders and the number of shares they intend to convert is provided, with the largest shareholder, Zhao Jiehui, holding 49,468,200 shares [4] - The total number of shares to be converted by all shareholders amounts to 300 million [4]